A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
-
REGULATORY LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
-
REGULATORY 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
-
REGULATORY AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
-
BUSINESS 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
-
REGULATORY Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
-
REGULATORY Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
-
ACADEMIA MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
-
ORGANIZATION Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
June 15, 2015
-
REGULATORY Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
-
REGULATORY Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
-
ORGANIZATION EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
-
BUSINESS Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
-
REGULATORY LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
-
ORGANIZATION Industry, Govt, Academia Should Discuss Challenges Facing Biosimilars: Prof. Kurokawa
June 9, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
-
REGULATORY Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 3: New Cancer Drugs Off to Strong Start
June 8, 2015
-
BUSINESS Lilly Japan Plans Excursion to Local Cities in Quest for Novel Drug Seeds
June 5, 2015
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…